NEW YORK (GenomeWeb News) – MDxHealth and Bostwick Laboratories today announced a marketing agreement covering MDxHealth's ConfirmMDx prostate cancer test.

The deal, they said, provides MDxHealth with access to one of the largest urology networks in the US. Bostwick specializes in anatomic and clinical pathology.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.